Iopidine

Apraclonidine, the active ingredient in Iopidine, is an Alpha-2 adrenergic agonist presented as a 0.5% ophthalmic solution for ocular use. It reduces intraocular pressure in patients with glaucoma and helps prevent ocular hypertension after eye surgery.

GNH USA supplies Iopidine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine, an Alpha‑2 adrenergic agonist, is employed in ocular conditions where lowering intraocular pressure is required.

- Glaucoma: lowers intraocular pressure to help preserve optic nerve function. - Post‑surgical ocular hypertension: prevents pressure spikes after ocular surgery. - Ocular hypertension: reduces elevated eye pressure in patients at risk of developing glaucoma.

Common Side Effects: - Ocular irritation or burning sensation. - Stinging upon instillation. - Transient blurred vision. - Conjunctival hyperemia (red eye). - Allergic conjunctivitis. - Dry eye sensation.

Serious or Rare Side Effects: - Severe ocular inflammation or uveitis. - Corneal edema or keratitis. - Systemic hypotension. - Bradycardia. - Anaphylactic-type allergic reaction. - Vision loss (very rare).

Before using Iopidine, consider the following precautions: - Monitor intraocular pressure regularly to assess therapeutic response. - Use with caution in patients with cardiovascular disease or systemic hypotension. - Avoid in individuals with known hypersensitivity to apraclonidine or formulation excipients. - Do not use in eyes with active severe inflammation or infection. - Concurrent use with other ocular vasoconstrictors should be evaluated by the prescriber. - Store at room temperature: keep in the original container, protect from light and moisture, and do not freeze.

Iopidine may interact with other medicines as follows:

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine): additive hypotensive effect. - Systemic antihypertensives: risk of excessive blood pressure reduction. - Other ocular alpha‑2 agonist preparations: potential over‑suppression of aqueous production.

Moderate Interactions (Monitor Closely):\n- Topical beta‑blocker eye drops: monitor intraocular pressure for additive effect. - Non‑steroidal anti‑inflammatory eye drops: may increase risk of ocular irritation. - Systemic MAO inhibitors: observe for cardiovascular changes.